Actuate Therapeutics' (ACTU) Buy Rating Reiterated at HC Wainwright

Key Points

• HC Wainwright has reaffirmed a "buy" rating for Actuate Therapeutics (NASDAQ:ACTU) with a price target of $20.00, indicating a potential upside of 146.31% from its current price.
• Actuate Therapeutics' stock opened at $8.12 and has shown a 52-week range between $5.47 and $11.99.
• Insider purchases have increased, with directors acquiring over 214,284 shares in recent months, signaling confidence in the company's future.

HC Wainwright reiterated their buy rating on shares of Actuate Therapeutics (NASDAQ:ACTU - Free Report) in a research note released on Monday,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock. HC Wainwright also issued estimates for Actuate Therapeutics' Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.05) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.02) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($0.99) EPS and FY2029 earnings at $0.21 EPS.

Separately, Craig Hallum assumed coverage on Actuate Therapeutics in a research report on Tuesday, April 22nd. They issued a "buy" rating and a $21.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $20.50.

Actuate Therapeutics Trading Up 9.1%

Shares of NASDAQ:ACTU traded up $0.70 during midday trading on Monday, reaching $8.36. The company had a trading volume of 58,818 shares, compared to its average volume of 64,528. Actuate Therapeutics has a 1-year low of $5.47 and a 1-year high of $11.99. The company has a fifty day simple moving average of $7.05 and a two-hundred day simple moving average of $7.94.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.11).

Insider Transactions at Actuate Therapeutics

In related news, Director Equity Cof Lp Bios purchased 71,428 shares of the firm's stock in a transaction that occurred on Friday, June 27th. The shares were acquired at an average price of $7.00 per share, with a total value of $499,996.00. Following the purchase, the director directly owned 196,428 shares in the company, valued at $1,374,996. This represents a 57.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Aaron G.L. Fletcher acquired 71,428 shares of Actuate Therapeutics stock in a transaction on Friday, June 27th. The stock was acquired at an average cost of $7.00 per share, for a total transaction of $499,996.00. Following the purchase, the director owned 196,428 shares of the company's stock, valued at approximately $1,374,996. This represents a 57.14% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 214,284 shares of company stock valued at $1,499,988. 69.34% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Actuate Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. BIOS Capital Management LP bought a new stake in shares of Actuate Therapeutics during the fourth quarter worth $78,753,000. Envestnet Asset Management Inc. acquired a new position in Actuate Therapeutics during the fourth quarter valued at approximately $83,000. Mercer Global Advisors Inc. ADV acquired a new position in Actuate Therapeutics during the fourth quarter valued at approximately $130,000. Voss Capital LP bought a new stake in Actuate Therapeutics in the fourth quarter valued at approximately $440,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Actuate Therapeutics in the fourth quarter valued at approximately $84,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.